Umoja Biopharma
PrivateLast Round
IPO
Apr 9, 2026
Est. Valuation
$420M
Total Funding Raised
$373M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Umoja Biopharma operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a Series C round in January 2025.
Umoja Biopharma is a biotechnology company that develops in vivo immunotherapies to reprogram a patient's immune system to fight cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Umoja Biopharma Comparables
Compare Umoja Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CREATE Medicines | 83% | |
| AbbVie | 81% | |
| Sana Biotechnology | 79% |
For institutional investors. Book with your work email.
Umoja Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Apr 9, 2026 | ||||
| Series C | Jan 14, 2025 | ||||
| Seed | Jan 9, 2024 | ||||
| Series B | Jun 15, 2021 | ||||
| Series A | Nov 18, 2020 | ||||
Seed | Nov 21, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Umoja Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MPM Capital | Series B, Seed, Series C, Series A |
| SoftBank Investment Advisers | Series C, Series B |
| Temasek | Series B |
| DCVC Bio | Series B, Seed, Series A, Series C |
| Cormorant Asset Management | Series C, Series B |
| Psalion VC | Seed |
| Orange DAO | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Completed an IPO round of funding.
- Apr 9, 2026
Opened a new cell/gene therapy GMP manufacturing facility in Louisville, CO.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 4, 2026
Umoja Biopharma presents four abstracts, including oral UB-VV400 clinical data, at the 68th ASH Annual Meeting in Louisiana in Dec '26.
For institutional investors. Book with your work email.
Umoja Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Umoja Biopharma's valuation, stock price, and market status.
Is Umoja Biopharma a public or private company?
Umoja Biopharma is a private company.
What is the current stock price of Umoja Biopharma?
Umoja Biopharma is a private company, so its shares have no public market price. Caplight tracks Umoja Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Umoja Biopharma worth (valuation)?
Umoja Biopharma's valuation is estimated at $420.0M based on funding round data.
Can I buy Umoja Biopharma stock?
Umoja Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Umoja Biopharma's last funding round?
Umoja Biopharma's most recent funding round was ipo on April 9, 2026.
Who are the main investors in Umoja Biopharma?
Key investors in Umoja Biopharma include MPM Capital, SoftBank Investment Advisers, DCVC Bio, Cormorant Asset Management, MPM BioImpact.
Will Umoja Biopharma IPO soon?
No public IPO plans have been announced for Umoja Biopharma.
How can I track Umoja Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Umoja Biopharma's shares on secondary markets.